<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881162</url>
  </required_header>
  <id_info>
    <org_study_id>SRM-2019-01</org_study_id>
    <nct_id>NCT04881162</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System</brief_title>
  <acronym>NITE1</acronym>
  <official_title>Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System In Transcarotid Embolectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silk Road Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silk Road Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid&#xD;
      Neuroprotection System when used for the transcarotid intervention of patients that have a&#xD;
      failed transfemoral endovascular therapy in the case of anterior circulation strokes due to&#xD;
      large vessel embolic occlusions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single arm feasibility study for the endovascular&#xD;
      treatment of patients with acute ischemic anterior circulation strokes due to large vessel&#xD;
      embolic occlusions using the transcarotid approach with flow reversal. Patients enrolled into&#xD;
      the NITE 1 Study will have failed transfemoral therapy and will be followed immediately from&#xD;
      post-op to 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with acute ischemic anterior circulation stroke due to large vessel embolic occlusion who are candidates for endovascular therapy and in whom transfemoral therapy failed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-related Serious Adverse Events</measure>
    <time_frame>procedure to 90 days</time_frame>
    <description>Vascular complications including dissection, pseudoaneurysm, hematoma, arteriovenous fistula, thrombus formation, embolization and any vascular complication that may be attributed to the device AND requires surgical repair, surgical wound revision, transfusion, etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Other Serious Adverse Events</measure>
    <time_frame>procedure to 90 days</time_frame>
    <description>Permanent cranial nerve injury, new symptomatic ipsilateral hemorrhage and dissections related to ancillary devices</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional independence at 90-days</measure>
    <time_frame>90 days</time_frame>
    <description>modified Rankin scale score 0-2 (out of a maximum scale of 6. A lower score indicates better outcome, a higher score indicates worse outcome)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>NOVIS Transcarotid Neuroprotection System (NPS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NOVIS Transcarotid Neuroprotection System (NPS)</intervention_name>
    <description>The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection</description>
    <arm_group_label>NOVIS Transcarotid Neuroprotection System (NPS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Summary:&#xD;
&#xD;
          -  1. Patients presenting with acute ischemic stroke of the anterior circulation with&#xD;
             large vessel occlusions who are eligible for revascularization using endovascular&#xD;
             therapies (stentrievers and/or aspiration devices)&#xD;
&#xD;
             2. Occlusion of the intracranial ICA or MCA-M1 segments&#xD;
&#xD;
             3. Patient has failed transfemoral therapy (see Appendix 4 for definition), and at&#xD;
             least 15 minutes have elapsed from groin puncture&#xD;
&#xD;
        Exclusion Criteria Summary:&#xD;
&#xD;
          -  1. Significant disease of the ipsilateral common carotid artery on routine CTA&#xD;
&#xD;
             2. Presence of a cervical ICA loop or other high-risk anatomical features of the ICA&#xD;
             on routine CTA, that may preclude the use of the NOVIS NPS&#xD;
&#xD;
             3. Any active or recent hemorrhage within the past 30 days&#xD;
&#xD;
             4. Embolectomy contraindications&#xD;
&#xD;
             a. Pre-stroke mRS ≥2 b. NIHSS ≤ 5 c. ASPECTS ≤ 5&#xD;
&#xD;
             5. IV tPA has been or is being administered&#xD;
&#xD;
             6. Last known well &gt; 24 hours ago&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Affairs Manager</last_name>
    <phone>408-585-2142</phone>
    <email>nhaque@silkroadmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Director Clinical Affairs</last_name>
    <phone>669-271-0501</phone>
    <email>dsahoo@silkroadmed.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mechanical thrombectomy</keyword>
  <keyword>stroke treatment</keyword>
  <keyword>embolic protection</keyword>
  <keyword>transcarotid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

